UWP
ACAD icon

Uniting Wealth Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Uniting Wealth Partners’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$278K Hold
11,000
– – 0.06% 157
2026
Q1 		$245K Hold
11,000
– – 0.05% 176
2025
Q4 		$294K Hold
11,000
– – 0.09% 115
2025
Q3 		$235K Hold
11,000
– – 0.06% 162
2025
Q2 		$237K Hold
11,000
– – 0.09% 94
2025
Q1 		$183K Hold
11,000
– – 0.09% 98
2024
Q4 		$202K Buy
+11,000
New +$178K 0.1% 94

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Uniting Wealth Partners's ACAD Position: Q2 2026 in Review

Uniting Wealth Partners held its Acadia Pharmaceuticals (ACAD) position steady in Q2 2026 at 11,000 shares worth $278K. The position accounts for 0.06% of the portfolio, ranked #157.

Uniting Wealth Partners first reported a position in ACAD in Q4 2024 and has held it in 7 quarters since. The position peaked at $294K in Q4 2025. 352 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Uniting Wealth Partners held 11,000 shares of Acadia Pharmaceuticals worth $278K as of Q2 2026.
  • Uniting Wealth Partners left its Acadia Pharmaceuticals share count unchanged in Q2 2026.
  • Acadia Pharmaceuticals made up 0.06% of Uniting Wealth Partners's portfolio in Q2 2026, its #157 holding.
  • Uniting Wealth Partners first reported a position in Acadia Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Uniting Wealth Partners's Acadia Pharmaceuticals position peaked at $294K in Q4 2025.
  • 352 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Uniting Wealth Partners's 13F filing for Q2 2026, filed 6 Aug 2026.